Skip to main content

Advertisement

SpringerLink
Log in

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

  • Original Article
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to analyze the prognostic factors associated with overall survival (OS) and progression-free survival (PFS) in patients with bone-only metastatic renal cell carcinoma (RCC) who have five or fewer lesions treated with stereotactic body radiotherapy (SBRT).

Methods

The clinical data of 54 patients with 70 bone metastases undergoing SBRT treated between 2013 and 2020 with a dose of at least 5 Gy per fraction and a biologically effective dose (BED) of at least 90 Gy were retrospectively evaluated.

Results

The majority of lesions were located in the spine (57.4%) and had only one metastasis (64.8%). After a median follow-up of 22.4 months, the 1‑ and 2‑year OS rates were 84.6% and 67.3%, respectively, and median OS was 43.1 months. The 1‑ and 2‑year PFS rates and median PFS were 63.0%, 38.9%, and 15.3 months, respectively. In SBRT-treated lesions, the 1‑year local control (LC) rate was 94.9%. Age, metastasis localization, and number of fractions of SBRT were significant prognostic factors for OS in univariate analysis. In multivariate analysis, patients with spinal metastasis had better OS compared to their counterparts, and patients who received single-fraction SBRT had better PFS than those who did not. No patient experienced acute or late toxicities of grade 3 or greater.

Conclusion

Despite excellent LC at the oligometastatic site treated with SBRT, disease progression was observed in nearly half of patients 13 months after metastasis-directed local therapy, particularly as distant disease progression other than the treated lesion, necessitating an effective systemic treatment to improve treatment outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284–291. https://doi.org/10.1016/j.ctrv.2011.06.011

    Article  PubMed  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

    Article  PubMed  Google Scholar 

  3. Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160–166. https://doi.org/10.1016/j.bone.2010.09.008

    Article  PubMed  Google Scholar 

  4. Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362

    Article  CAS  PubMed  Google Scholar 

  5. Santini D, Procopio G, Porta C et al (2013) Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Plos One 8(12):e83026. https://doi.org/10.1371/journal.pone.0083026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Santoni M, Conti A, Procopio G et al (2015) Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res 34:10. https://doi.org/10.1186/s13046-015-0122-0

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kalra S, Verma J, Atkinson BJ et al (2017) Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 15(3):363–370. https://doi.org/10.1016/j.clgc.2017.01.010

    Article  PubMed  Google Scholar 

  8. McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577–584. https://doi.org/10.1016/j.eururo.2013.08.012

    Article  PubMed  Google Scholar 

  9. Dabestani S, Marconi L, Hofmann F et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561. https://doi.org/10.1016/S1470-2045(14)70235-9

    Article  PubMed  Google Scholar 

  10. Grunwald V, Eberhardt B, al Bex A (2018) An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 15(8):511–521. https://doi.org/10.1038/s41585-018-0034-9

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8

    Article  CAS  PubMed  Google Scholar 

  12. Meyer E, Pasquier D, Bernadou G et al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG group. Eur J Cancer 98:38–47. https://doi.org/10.1016/j.ejca.2018.04.008

    Article  PubMed  Google Scholar 

  13. Wang CJ, Christie A, Lin MH et al (2017) Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 98(1):91–100. https://doi.org/10.1016/j.ijrobp.2017.01.032

    Article  PubMed  PubMed Central  Google Scholar 

  14. Marvaso G, Corrao G, Oneta O et al (2021) Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 23(8):1717–1726. https://doi.org/10.1007/s12094-021-02574-0

    Article  CAS  PubMed  Google Scholar 

  15. Franzese C, Marvaso G, Francolini G et al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38(6):527–537. https://doi.org/10.1007/s10585-021-10131-w

    Article  PubMed  Google Scholar 

  16. Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519–2528

    CAS  PubMed  Google Scholar 

  17. Guerrero M, Li XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49(20):4825–4835. https://doi.org/10.1088/0031-9155/49/20/012

    Article  CAS  PubMed  Google Scholar 

  18. Song CW, Lee YJ, Griffin RJ et al (2015) Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93(1):166–172. https://doi.org/10.1016/j.ijrobp.2015.05.016

    Article  PubMed  PubMed Central  Google Scholar 

  19. Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88(2):254–262. https://doi.org/10.1016/j.ijrobp.2013.07.022

    Article  PubMed  PubMed Central  Google Scholar 

  20. Park HJ, Griffin RJ, Hui S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311–327. https://doi.org/10.1667/rr2773.1

    Article  CAS  PubMed  Google Scholar 

  21. Kothari G, Foroudi F, Gill S et al (2015) Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 54(2):148–157. https://doi.org/10.3109/0284186X.2014.939298

    Article  CAS  PubMed  Google Scholar 

  22. Ruhle A, Andratschke N, Siva S, Guckenberger M (2019) Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104–112. https://doi.org/10.1016/j.ctro.2019.04.012

    Article  PubMed  PubMed Central  Google Scholar 

  23. Altoos B, Amini A, Yacoub M et al (2015) Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol 10:218. https://doi.org/10.1186/s13014-015-0528-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. https://doi.org/10.1093/annonc/mdq554

    Article  CAS  PubMed  Google Scholar 

  25. Zaorsky NG, Lehrer EJ, Kothari G et al (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies. Eur Urol Oncol 2(5):515–523. https://doi.org/10.1016/j.euo.2019.05.007

    Article  PubMed  Google Scholar 

  26. Zelefsky MJ, Greco C, Motzer R et al (2012) Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82(5):1744–1748. https://doi.org/10.1016/j.ijrobp.2011.02.040

    Article  PubMed  Google Scholar 

  27. De B, Venkatesan AM, Msaouel P et al (2021) Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. https://doi.org/10.1111/bju.15541

    Article  PubMed  Google Scholar 

  28. Zhang Y, Schoenhals J, Christie A et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105(2):367–375. https://doi.org/10.1016/j.ijrobp.2019.07.023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ranck MC, Golden DW, Corbin KS et al (2013) Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 36(6):589–595. https://doi.org/10.1097/COC.0b013e31825d52b2

    Article  CAS  PubMed  Google Scholar 

  30. Cheung P, Patel S, North SA et al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study. Eur Urol 80(6):693–700. https://doi.org/10.1016/j.eururo.2021.07.026

    Article  CAS  PubMed  Google Scholar 

  31. Spencer KL, van der Velden JM, Wong E et al (2019) Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 111(10):1023–1032. https://doi.org/10.1093/jnci/djz101

    Article  PubMed  PubMed Central  Google Scholar 

  32. Sahgal A, Larson DA, Chang EL (2008) Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71(3):652–665. https://doi.org/10.1016/j.ijrobp.2008.02.060

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, 01120, Adana, Turkey

    Cem Onal & Ozan Cem Guler

  2. Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Pervin Hurmuz, Burak Tilki & Gokhan Ozyigit

  3. Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey

    Cem Onal, Guler Yavas & Cagdas Yavas

  4. Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey

    Ezgi Oymak

Authors
  1. Cem Onal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozan Cem Guler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pervin Hurmuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guler Yavas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Burak Tilki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ezgi Oymak
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cagdas Yavas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gokhan Ozyigit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cem Onal.

Ethics declarations

Conflict of interest

C. Onal, O.C. Guler, P. Hurmuz, G. Yavas, B. Tilki, E. Oymak, C. Yavas, and G. Ozyigit declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onal, C., Guler, O.C., Hurmuz, P. et al. Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study. Strahlenther Onkol 198, 940–948 (2022). https://doi.org/10.1007/s00066-022-01962-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-01962-x

Keywords

Search

Navigation